Gilead touts new data for fast-growing Biktarvy as older HIV meds show some cracks

gilead4
Gilead is riding the success of HIV med Biktarvy as its HIV portfolio and overall sales dwindle. (Gilead)

Amid Gilead Sciences' flagging sales, HIV med Biktarvy has been a rare shining light with growth nearly quadrupling in the last year. Hoping to capitalize on its next-gen HIV portfolio's success, Gilead it touting new data for Biktarvy and Truvada follow-up Descovy that could help pad their cases. 

Biktarvy measured up to two treatment regimens, including archrival ViiV Healthcare's Tivicay, in suppressing symptoms of HIV in newly treated patients at the 144-week mark, according to data from two phase 3 clinical trials released Wednesday. 

Gilead said in a statement the two studies helped reinforce Biktarvy's strength in newly diagnosed patients.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

The drug once again showed it's "an effective treatment that offers durable viral suppression and maintains a high barrier to resistance,” said Diana Brainard, Gilead's senior VP for HIV and emerging viruses. “These longer-term data reaffirm Biktarvy’s role as a first-line treatment option.”

RELATED: Gilead's ready to spend big on Descovy, filgotinib launches as hep C and Yescarta struggle: CEO

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.